Literature DB >> 28008457

Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis.

Predrag Ostojic1,2, Natasa Stojanovski3.   

Abstract

The aim of this study was to estimate prevalence and severity of renal insufficiency in systemic sclerosis (SSc) and to assess risk factors associated with reduced glomerular filtration rate (GFR) in SSc patients. Seventy-three consecutive patients with SSc (67 women and 6 men), mean age 56.2 years, mean disease duration 6.7 years, were included in this cross-sectional study. GFR was measured by creatinine clearance (CCr) in all patients, as well as 24-h proteinuria. We assessed frequency and severity of renal insufficiency in our patients with SSc and estimated the association of renal insufficiency with age, disease duration, subtype of the disease, earlier diagnosed arterial hypertension, and medications for which we assumed to affect renal function-cytostatics, nonsteroidal anti-inflammatory drugs, glucocorticoids, ACE inhibitors, diuretics, and calcium channel blockers (CCB). Fifty-six out of 73 patients with SSc (76.7%) had reduced GFR (CCr lower than 90 ml/min), compared to 17/73 (23.3%) of patients with normal renal function. Mild renal insufficiency was noticed in 28/73 (38.4%), moderate in 21/73 (28.8%) and severe renal insufficiency in 5/73 (6.8%). End-stage renal disease (CCr < 15 ml/min) was found in 2/73 (2.7%) of patients. Using the univariate general linear statistical model, we have found that previously diagnosed arterial hypertension and treatment with glucocorticoids are independent risk factors for reduced GFR. On the other hand, age, disease duration, disease form, as well as antibodies (anticentromere antibodies-ACA and anti-topoisomerase I antibodies-ATA) were excluded as independent risk factors. Patients with SSc and arterial hypertension treated with CCB had significantly higher mean CCr than patients treated with diuretics (90.4 vs 53.5 ml/min, p = 0.03), or patients treated with ACE inhibitors (90.4 vs 41.7 ml/min, p = 0.001). Decreased GFR is common in SSc. Most of patients have mild or moderate renal insufficiency. Previously diagnosed arterial hypertension, especially when treated with ACE inhibitors or diuretics, and glucocorticoids are independent risk factors associated with reduced GFR in SSc. These medications should be therefore used with caution in SSc patients.

Entities:  

Keywords:  Renal insufficiency; Risk factors; Systemic sclerosis

Mesh:

Substances:

Year:  2016        PMID: 28008457     DOI: 10.1007/s00296-016-3632-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

Review 3.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

Review 4.  The clinical significance of inhibition of renal prostaglandin synthesis.

Authors:  C Patrono; M J Dunn
Journal:  Kidney Int       Date:  1987-07       Impact factor: 10.612

5.  Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure.

Authors:  M S Weinfeld; G M Chertow; L W Stevenson
Journal:  Am Heart J       Date:  1999-08       Impact factor: 4.749

6.  Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease.

Authors:  Predrag Ostojić; Nemanja Damjanov; Slavica Pavlov-Dolijanovic; Goran Radunović
Journal:  Clin Hemorheol Microcirc       Date:  2004       Impact factor: 2.375

7.  Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure.

Authors:  A K Mandal; R J Markert; M G Saklayen; R A Mankus; K Yokokawa
Journal:  Clin Nephrol       Date:  1994-09       Impact factor: 0.975

8.  Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis.

Authors:  S I Nihtyanova; G M Brough; C M Black; C P Denton
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

9.  Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment.

Authors:  E J Kingdon; C J Knight; K Dustan; A G Irwin; M Thomas; S H Powis; A Burns; A J W Hilson; C M Black
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

10.  Scleroderma renal crisis: patient characteristics and long-term outcomes.

Authors:  H Penn; A J Howie; E J Kingdon; C C Bunn; R J Stratton; C M Black; A Burns; C P Denton
Journal:  QJM       Date:  2007-06-29
View more
  4 in total

Review 1.  Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.

Authors:  Elena Bartoloni; Alessia Alunno; Roberto Gerli
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 2.  Role of Inflammatory Diseases in Hypertension.

Authors:  E Bartoloni; A Alunno; V Valentini; F Luccioli; E Valentini; G La Paglia; O Bistoni; Roberto Gerli
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-09

3.  Trigonelline reverses high glucose-induced proliferation, fibrosis of mesangial cells via modulation of Wnt signaling pathway.

Authors:  Chen Chen; Yan Shi; Jiulong Ma; Zhen Chen; Ming Zhang; Yan Zhao
Journal:  Diabetol Metab Syndr       Date:  2022-02-09       Impact factor: 3.320

4.  A risk scoring system for the decreased glomerular filtration rate in Chinese general population.

Authors:  Yan Gu; Min Chen; Bei Zhu; Xiaohua Pei; Zhenzhu Yong; Xiaona Li; Qun Zhang; Weihong Zhao
Journal:  J Clin Lab Anal       Date:  2019-12-22       Impact factor: 2.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.